Literatura académica sobre el tema "Recherche de biomarqueurs"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Recherche de biomarqueurs".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Recherche de biomarqueurs"
Svenningsson, Anders y et Barry A. Hendin. "Paramètres cliniques, biochimiques et dimagerie prédictifs de I évolution de la sclérose en plaques". European Neurological Review 8, (Suppl.1) (2013): 10. http://dx.doi.org/10.17925/enr.2013.08.s1.10a.
Texto completoBonifay, Amandine, Sandra Ghayad, Romaric Lacroix y Françoise Dignat-George. "Biomarqueurs vésiculaires". médecine/sciences 37, n.º 12 (diciembre de 2021): 1158–65. http://dx.doi.org/10.1051/medsci/2021208.
Texto completoHenry, C. "Le trouble bipolaire et ses biomarqueurs : quoi de neuf ?" European Psychiatry 29, S3 (noviembre de 2014): 557. http://dx.doi.org/10.1016/j.eurpsy.2014.09.364.
Texto completoLadet, Julien y Franck Mortreux. "Les ARN circulaires, acteurs et biomarqueurs dans le cancer". médecine/sciences 36, n.º 10 (octubre de 2020): 935–38. http://dx.doi.org/10.1051/medsci/2020165.
Texto completoBaron-Bodo, V., S. Horiot, H. Moussu, K. Jain, J. Bouley, A. C. Rimaniol, G. Peltre et al. "À la recherche de biomarqueurs de l’immunothérapie allergénique sublinguale". Revue Française d'Allergologie 52, n.º 3 (abril de 2012): 274–75. http://dx.doi.org/10.1016/j.reval.2012.02.066.
Texto completoGaille, Marie, Marco Araneda, Clément Dubost, Clémence Guillermain, Sarah Kaakai, Élise Ricadat, Nicolas Todd y Michael Rera. "Conséquences éthiques et sociales de biomarqueurs prédictifs de la mort chez l’homme". médecine/sciences 36, n.º 12 (diciembre de 2020): 1199–206. http://dx.doi.org/10.1051/medsci/2020228.
Texto completoRai, Alex J. "La déplétion des protéines abondantes à la recherche de biomarqueurs protéiques". médecine/sciences 23 (marzo de 2007): 5–8. http://dx.doi.org/10.1051/medsci/2007231s5.
Texto completoDHENAIN, Marc. "STRATEGIE DE RECHERCHE TRANSLATIONNELLE SUR LA MALADIE D'ALZHEIMER : MODÈLES ANIMAUX ET BIOMARQUEURS". Bulletin de l'Académie vétérinaire de France, n.º 1-4 (2013): 346. http://dx.doi.org/10.4267/2042/53061.
Texto completoClaustre, J., C. Trocmé, S. Bourgoin-Voillard, H. Flamant-Waret, I. Bérard, B. Toussaint, K. Botturi-Cavaillès et al. "Recherche de biomarqueurs prédictifs de rejet chronique d’allogreffe pulmonaire par analyses protéomiques". Revue des Maladies Respiratoires 32 (enero de 2015): A250. http://dx.doi.org/10.1016/j.rmr.2014.10.708.
Texto completoCautela, J. "Place des biomarqueurs dans la recherche de toxicité cardiaque en cardio-oncologie". Oncologie 18, n.º 1 (enero de 2016): 9–16. http://dx.doi.org/10.1007/s10269-015-2578-4.
Texto completoTesis sobre el tema "Recherche de biomarqueurs"
Lemesle, Gilles. "Recherche de biomarqueurs pronostiques dans l'insuffisance cardiaque". Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S028/document.
Texto completoRisk stratification of patients with systolic chronic heart failure (HF) is critical to better identify those who may benefit the most from invasive therapeutic strategies such as cardiac transplantation. In spite of recent advances, risk stratification of HF patients needs to be further improved. Indeed, there remains variability in the prognosis with some patients who are categorized at low risk but experience early mortality; and conversely, patients categorized as severe but have an unexpectedly prolonged survival. Proteomics has been used to provide prognostic information in various diseases.Aim – Our aim was to investigate the potential value of plasma proteomic profiling for risk stratification in HF and to find new circulating biomarkers that are associated with early cardiovascular mortality of chronic HF patients.Methods and results – For that purpose, we first designed 2 populations: a discovery and a validation population. Both populations issued from the INsuffisance CArdiaque (INCA) cohort, which is constituted of all consecutive patients referred in our institution for extensive prognostic evaluation of systolic chronic HF (LVEF <45%) between November 1998 and May 2010. For the discovery phase (case/control population), we selected 198 patients included between November 1998 and December 2005: 99 patients who died from cardiovascular cause within 3 years after the initial evaluation (cases) were individually matched for age, sex, and HF etiology with 99 patients who were still alive at 3 years (controls). For the validation phase, we evaluated a cohort of 344 consecutive patients included between January 2006 and May 2010. Study populations were carefully phenotyped. Cardiovascular death included cardiovascular-related death, urgent transplantations defined as United Network for Organ Sharing status 1 and urgent assist device implantation. A proteomic profiling using surface enhanced laser desorption ionization - time of flight - mass spectrometry was then performed in the case/control discovery population on plasma samples collected at inclusion. Plasma samples were depleted for major proteins and randomly analyzed in duplicate using CM10 (Weak Cation Exchanger) and H50 (Reverse Phase) proteinchip arrays. Forty two ion m/z peaks were found differentially abundant between cases and controls in the discovery population and were used to develop proteomic scores predicting cardiovascular death using 3 statistical regression methods: support vector machine, sparse partial least square discriminant analysis and lasso logistic regression. The proteomic scores were then tested in the validation population and score levels were significantly higher in patients who subsequently died within 3 years with the 3 methods. Proteomic scores remained significantly associated with cardiovascular mortality after adjustment on confounders. Furthermore, use of the proteomic scores allowed a significant improvement in discrimination of HF patients as determined by integrated discrimination improvement and net reclassification improvement indexes on top of “classic” prognostic evaluation. The next step was the purification and identification of the proteins related to the different m/z peaks (n=13) that were found significantly differentially abundant in both populations. We have currently identified several peaks as apolipoproteins: 14511 CM10-BM (ApoA1), 29024 CM10-BM (ApoA1), 3267 H50-BM (ApoC1), 6416 H50-BM (ApoC1), 6616 H50-BM (ApoC1), 6825 H50-BM (ApoC1), 8764 H50-BM (ApoC3), 9421 H50-BM (ApoC3). This has led to the quantification of these apolipoproteins in the INCA population using mass reaction monitoring technique.Conclusion – Proteomic analysis of plasma proteins may help to improve risk prediction of early mortality in HF patients.Perspectives – Further investigations are ongoing in order to determine the impact of the different apolipoproteins tested in risk stratification of chronic HF patients
Acosta, Martin Adelina Elena. "Recherche de biomarqueurs de l'anévrysme de l'aorte abdominale". Phd thesis, Université du Droit et de la Santé - Lille II, 2009. http://tel.archives-ouvertes.fr/tel-00447240.
Texto completoRobert, Rémy. "Recherche de biomarqueurs pour l'imagerie moléculaire de l'athérosclérose". Bordeaux 2, 2006. http://www.theses.fr/2006BOR21324.
Texto completoThis thesis is divided in two parts. Its aim is the development of human monoclonal antibodies of cardiovascular interest. The first part involves the production, the purification and the biochemical analysis of human antibody fragments directed against the αIIbβ3 integrin. The second part described the in vivo selection by phage display of human scFvs targeting atherosclerotic lesions. We have screened in vivo the atherosclerotic plaques of this model with two different combinatorial libraries of human antibodies. Our strategy is based on a substractive screening with normal and atherosclerotic protein-coated filters, allowing the detection of scFvs after one round of in vivo biopanning. This substractive aproach has permitted us to isolate two scFvs specific to atherosclerotic proteins. The development of such antibodies could be useful : (1) in diagnosis for the early detection of atherosclerotic lesions by MRI, (2) in gene therapy, to improve the molecular targeting
Szacherski, Pascal. "Reconstruction de profils protéiques pour la recherche de biomarqueurs". Phd thesis, Université Sciences et Technologies - Bordeaux I, 2012. http://tel.archives-ouvertes.fr/tel-00788410.
Texto completoNegroni, Luc. "Analyse phosphoprotéomique pour la recherche de biomarqueurs : développements et applications". Phd thesis, Université Sciences et Technologies - Bordeaux I, 2013. http://tel.archives-ouvertes.fr/tel-00965662.
Texto completoBen, Ameur Siala Randa. "Recherche de biomarqueurs précoces de diagnostic de la néphropathie diabétique". Thesis, Montpellier 2, 2011. http://www.theses.fr/2011MON20004.
Texto completoDiabetic nephropathy (DN) is one of the most serious complications of diabetes. It affects about 30% of diabetic patients. Microalbuminuria is currently the main available marker for DN risk, but has inadequate specificity and precocity. Several published studies intended to research new biomarkers (BM) of DN by proteomic approaches. We have shown1 that, if several candidate BM were claimed, there was no consensus about their nature and that a number of studies could not identify BM earlier than albumin because of the study design. Thus, we have selected an original cohort of type 1 diabetic patients considered at risk of developing DN, on the basis of urinary albumin excretion after an exercice test. A control cohort was also enrolled. Using 2D gel electrophoresis we compared the urinary proteomes of patients from both cohorts. Then, candidate BM were identified by mass spectrometry. Functional analysis of these proteins showed that some are involved in the coagulation cascade and in mechanisms of endothelial dysfunction. The diagnostic potential of these proteins was validated by Western blotti ng. The nature and physiological function of candidate biomarkers allowed to better understand the molecular pathogenic mechanisms of DN. Results from this part of the work are shown in the form of an article2. Preliminary studies to assess the diagnostic potential research of specific urinary proteins (nephrin and different isoforms of adiponectin) are also presented.1 Ben Ameur R. et al Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 25, 2866-752 Ben Ameur R. et al Identification of early candidate biomarkers for diabetic nephropathy by urine proteomic analysis. To be submitted
Collignon, Olivier. "Recherche statistique de biomarqueurs du cancer et de l'allergie à l'arachide". Phd thesis, Nancy 1, 2009. http://tel.archives-ouvertes.fr/tel-00430177.
Texto completoLe, Faouder Julie. "Recherche de biomarqueurs tissulaires de la cancerogenèse hépatique par imagerie Maldi". Paris 7, 2012. http://www.theses.fr/2012PA077002.
Texto completoHepatocellular carcinoma (HCC) represents the sixth most common cancer in the world, and the third most frequent oncological cause of death. Over 80% of HCC develop from cirrhosis, mainly related to viral etiology. The prognosis of HCC is mostly poor, because of its late detection at an advanced stage. Thus, new effective biomarkers are needed. MALDI imaging mass spectrometry (MALDI IMS) allows differential distribution visualization of potential markers within tissue. The aim of the present project was to investigate, using MALDI IMS, the proteome of HCC and to compare it with peritumoral cirrhosis so as to characterize new biomarkers of HCC. We found a set of proteins/peptides with a differential intensity level that most accurately delineated cancer from adjacent cirrhotic tissue. We generated a classification model enabling correct classification of most spectra present in cirrhosis or tumor areas from the independent validation group. The most discriminating marker (m/z 8,565) increased in HCC was characterized as the monomeric ubiquitin and further validated by immunohistochemistry. Marker m/z 2,753 was a peptidic fragment of albumin and was overexpressed in HCC while m/z 3,195, identified as a fragment of the alpha chain of hemoglobin, was specifically more intense in cirrhosis. This work provides complementary tools that could be useful in the early diagnosis of HCC. Identified biomarkers will gain further insights in the role of proteasome in the liver cancerogenesis. MALDI IMS and identification developed methods will be useful for other projects
Hinsinger, Geoffrey. "Recherche de biomarqueurs biologiques de sclérose en plaques par protéomique quantitative". Thesis, Montpellier, 2016. http://www.theses.fr/2016MONTT027.
Texto completoDiscovery, confirmation and verification of candidate biomarkers for multiple sclerosis diagnosis and prognosis in cerebrospinal fluid.Multiple sclerosis (MS) is an inflammatory disease of the central nervous system. Most often the disease initiates by a first demyelinating event called clinically isolated syndrome (CIS), followed by remission periods and relapses occurring at irregular intervals. Clinical symptoms and MRI are used for diagnosis, but clinicians lack tools to predict the rate of disease progression. This study aims at identifying biomarkers that predict the delay of conversion to MS after a CIS. We compared the cerebrospinal fluid (CSF) proteome from MS patients and symptomatic controls and the CSF from CIS patients with rapid conversion to MS (<1 year) and CIS patients with slow conversion to MS (>2 years). For the discovery step, human CSF samples (n=40) depleted of the 20 major plasma proteins were digested using a modified filter-assisted sample preparation (FASP) and analysed by high-resolution mass spectrometry using isobaric mass tag labelling or label-free quantification procedures. Proteins upregulated in CSF from MS patients included two proteins involved in tissue remodeling, namely chitinase-3-like protein-1 (CHI3L1) and chitinase-3-like protein-2 (CHI3L2). Their increased level in CSF of MS patients was confirmed by ELISA in a new cohort comprising CIS and MS patients (n=123) at different disease stages. Moreover, CHI3L1 levels in CSF and serum from CIS patients discriminated patients with rapid conversion to MS (< one year) from those with slower conversion.We also implemented a PRM method (peptide selection, dilution optimization of heavy isotope labeled non-purified peptides, reproducibility evaluation and method validation) to qualify a larger set of candidate biomarkers (226 peptides corresponding to 87 proteins) in a cohort different from the one used for the discovery step (n=60), including CSF from controls and MS patients at different disease stages. Finally, to further verify the 11 candidate biomarkers that passed this qualification step, we monitored 16 peptides in a new PRM assay, using shorter gradient and high-purity heavy isotope labeled peptides. This new PRM analysis was performed on a larger cohort (n=189) that included CSF of patients with other inflammatory and non-inflammatory neurological disorders in addition to control and MS patients. These analyses identified seven robust candidate biomarkers, which might help to discriminate patients suffering from MS or other neurological disorders
Bodet, Pierre-Edouard. "Recherche de biomarqueurs glucidiques de mucopolysaccharidoses et étude de la physiopathologie". Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLE001/document.
Texto completoThe identification of biomarkers remains one of the main challenges for analytical sciences and a major stake for clinical research. Glycosaminoglycans (GAGs) have been identified as potential biomarkers of mucopolysaccharidoses (MPS) belonging to rare genetic diseases with often a deadly issue. These pathologies are due to a deficiency in one of the enzymes responsible for GAGs catabolism. This enzymatic defect results in the accumulation of partially catabolized GAGs in organism and leads to neurodegeneration for the most severe forms of the disease. GAGs are complex polyanionic polysaccharides involved in numerous physiological processes in mammals. Their study remains a challenging task because of their high structural heterogeneity and their low biodisponibility, besides the lack of dedicated analytical tools. Our aim was to detect and quantify these compounds in biologic fluids such as urine and cerebrospinal fluid, and to elucidate their structures by mass spectrometry. This study focused on heparan sulfate (HS) oligosaccharides, as potential biomarkers of MPS featured by neurological manifestations (MPS I, IIIB and IIIC), and possibly responsible of lesions in the central nervous system. An experimental strategy allowing the extraction of HS oligosaccharides from biological fluids was implemented, thereby the structures of urinary heparan sulfate oligosaccharides were deciphered, leading to possible biomarkers candidates of MPS IIIB and IIIC. These compounds could be useful for diagnostic and patient follow-up that are currently lacking for the monitoring of therapeutic assays. In vitro exposition of different cerebral cell types to HS oligosaccharides was carried out to establish the relation between the structure of oligosaccharides and neuropathological effects. These studies highlighted several cellular processes that could be involved in neurodegeneration and constitute new therapeutic targets
Capítulos de libros sobre el tema "Recherche de biomarqueurs"
Robert, M., M. Campone y J. S. Frenel. "Biomarqueurs, recherche translationnelle et essais cliniques précoces". En Les biomarqueurs moléculaires en oncologie, 29–36. Paris: Springer Paris, 2014. http://dx.doi.org/10.1007/978-2-8178-0445-3_3.
Texto completo